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Abstract
Acromegaly is a rare, indolent disease due to
overproduction of growth hormone. Surgery is identified
as primary treatment, but has its limitation, thus
frequently requiring alternate treatment options as
adjunct to surgery. Stereotactic radiosurgery (SRS) has
been used as adjuvant and alternate therapy in patients
with inoperable or residual disease; or those not fit for
surgery. It has shown reasonable results for treating
macroadenoma and tumours invading cavernous sinuses
with significant reduction in tumour size and durable
endocrinological remission. Factors favouring better
outcomes include time from last resection to SRS, older
age, peri-procedural withdrawal of medication, higher
margin and maximum dose.Hypopituitarism is the most
common side effects and requires yearly screening. With
the new advances in the field Fractionated-stereotactic
radiosurgery and cyber-knife robotic radiosurgery have
been introduced with promising preliminary results..
Keywords: Pituitary adenoma, acromegaly, radiation
therapy.
Background
Acromegaly has estimated prevalence of 36-69 per
million population worldwide1-4. It is an endocrinological
disorder of the pituitary gland due to abnormally
increased secretion of Growth Hormone (GH)1,4causing
pathagnomonic symptoms of increased blood pressure
and enlarged hands and feet.5 Acromegaly is associated
with high morbidity and mortality rates, that are as high
as 2-3 times compared to the general population.
The treatment goals for acromegaly are reduction of GH
level, normal range Insulin-like Growth Factor-I (IGF-I),
tumour shrinkage and control of clinical symptoms.
According to a highly cited expert consensus, surgery is
identified as the primary treatment, especially for small,
well-circumscribed adenomas5. However, surgery is not
curative for certain macroadenoma and invasive tumours,
especially the ones invading cavernous sinus. In addition
to traditional surgical and medical treatment options, SRS
is now increasingly recognized as another treatment
option6,7. 
Review of Evidence
We searched “Stereotactic Radiosurgery (SRS) for
acromegaly” on PubMed and the articles were reviewed.
Radiosurgery has evolved tremendously in past 20 years,
with increased efficiency and improved side effects
profile. With the advent of new technology, now it is
much focused and can be delivered in one dose after 3-D
mapping of the lesion, called Stereotactic Radiosurgery
(SRS), or in multiple smaller doses, called Fractionated-
Stereotactic Radiosurgery (FSRT). Multiple technologies
for radiation delivery are available, using photons
(Gamma knife, Cyber knife, LINAC) or charged particles
(protons)6. 
The role of radiosurgery in the treatment of acromegaly
has been widely studied but paucity of a large patient
population and longer follow-up has limited the
evaluation of long term outcomes. Recently, a large,
international, multi-centric study pooled and analyzed
patient cohorts from 10 institutions participating in
International Gamma Knife Research Foundation and
reported promising results. In total 371 patients were
enrolled with minimum follow-up of 6 months. The initial
endocrinological remission rate was 69% and calculated
durable endocrinological remission rate at 10 years, was
59%. Mean time for durable remission and recurrence
after durable remission was 38 and 17months,
respectively8. 
In a recent meta-analysis, a mean reduction of 93-100% in
tumour size was been reported with mean tumour
control of 98% and endocrinological remission of 44.3%
at median follow up of 59 months.This meta-analyses
showed a better disease control with SRS (52%) compared
to conventional radiotherapy (36%) at 5 years but the
difference was not significant7. The main goal of all the
studies have been to identify important factors favouring
early durable endocrinological remission, so that patient
selection and efficiency of this rapidly evolving
technology may be improved. The factors showing strong
association with favourable outcomes can be divided
into, patients dependent (older age, decreased time
between last resection and first radiotherapy session,
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densely granulated tumour and temporary withholding
of IGF-I lowering medications prior to treatment and SRS
dependent(higher margin radiation dose, higher
maximum dose, whole sella radiosurgery and
radiosurgery to cavernous sinus7-9. 
With the increasing use of this modality it is important to
understand the limitations and side effects of SRS. The
most important side effects include radiation induced
hypopituitarism, optic neuropathy and other cranial
neuropathies, radionecrosis and cerebrovascular disease.
Hypopituitarism is the most commonly experienced side
effect, which may present in a delayed fashion, and can be
predicted by cavernous sinus extension in pre-SRS
imaging. The risk for delayed hypopituitarism increases as
a function of time, as Cohen-Inbar et al,. reported the
actuarial rates of 2%, 12%, 26% after 3, 5 and 10 years of
SRS, respectively. This mandates yearly assessment of
endocrine profile of all patients undergoing SRS 5,10. SRS is
also not advised for large invasive adenoma and for those
which are in closer proximity to optic chiasm6.Joint
venture of biotechnology sciences and physics have
introduced many innovation in the field, including FSRT, a
novel hybrid technology that may improve outcomes and
overcome limitations of SRS. It allows the delivery of
focused radiation in multiple doses, delivering on average
a dose of 45-55Gy in 25-33 daily fractions. Its use is
recommended for large adenomas (>3cm) and for
tumours located at the distance of 3-5mm from optic
chiasm.Although more outcome studies with longer
follow up are still awaited for this modality, but initial
results have been promising, showing tumour reduction
comparable to that of SRS and conventional radiation
therapy. The incidence of cranial neuropathies and
cerebral necrosis is less than SRS but risk of
cerebrovascular event is higher6 Recently, experience
with cyber-knife robotic surgery at a single institution was
reported to have similar tumour control, but with much
fewer visual complications and fewer cases of
hypopituitaris.11
Conclusion
Surgery remains the treatment of choice for acromegaly,
However, for cases with residual, recurrent or inoperable
tumours, SRS is also a valid option especially as an adjunct
to surgery. It may also be used in patients who cannot
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Figure-1: MRI brain T1 with contrast axial, sagittal and coronal images of a growth hormone secreting giant pituitary adenoma with temporal and suprasellar extension.
Figure-2: Post-operative images of the same patient after trans-cranial and trans-sphenoidal resection, showing a small residual tumor in right peri-mesencephalic
cistern, that was managed with SRS.
undergo surgery. With improving technology, the
existing limitations of SRS may be overcome, however,
until then, referring patients for SRS must be weighed
against the complications of treatment. Therefore, patient
selection is extremely important.
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